HighGravityDataBioMarin Pharmaceutical — Oct 29, 2024 release
Fiscal 2024 third-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001048477-24-000149
Showing in the filing
Weighted-Average Diluted Shares Outstanding assumption
“approximately 200 million”
Period
FY2024
Measure
Company-defined measure
Source
Guidance table
All guidance in this release · 12
VOXZOGO country access expansion for FY2027
“more than 20 additional countries”
Total Revenues for FY2027
“Approximately $4 billion”
Non-GAAP Operating Margin for FY2026
“40%”
Non-GAAP Operating Margin
“low- to mid-40% range”
Operating cash flow for FY2027
“More than $1.25 billion”
Total revenues CAGR for FY2034
“Mid-teen compound annual growth rate (CAGR)”
Total revenues compound annual growth rate (… for FY2034
“Mid-teen”
Treatments for Skeletal Conditions revenue o…
“greater than $5 billion”
Total Revenues for FY2024
“$2,790 to $2,825”
Non-GAAP Operating Margin % for FY2024
“26.5% to 27.5%”
Non-GAAP Diluted EPS for FY2024
“$3.25 to $3.35”
Weighted-Average Diluted Shares Outstanding … for FY2024
“approximately 200 million”
Exhibit 99.1 · the passage around this item
… earlier in the release
2024 Full-Year Financial Guidance (in millions, except % and EPS amounts) (Updated) Item Provided August 5, 2024 Updated October 29, 2024 Total Revenues $2,750 to $2,825 $2,790 to $2,825 Non-GAAP Operating Margin % (1) 26% to 27% 26.5% to 27.5% Non-GAAP Diluted EPS (1)(2) $3.10 to $3.25 $3.25 to $3.35 (1) Refer to Non-GAAP Information beginning on page 10 of this press release for definitions of Non-GAAP Operating Margin and Non-GAAP Diluted EPS. (2) Non-GAAP Diluted EPS guidance assumes approximately 200 million Weighted-Average Diluted Shares Outstanding. BioMarin will host a conference call and webcast to discuss third quarter 2024 financial results today, Tuesday, October 29, 2024, at 4:30 p.m. ET. This event can be accessed through this link or on the investor section of the BioMarin website at www.biomarin.com. U.S./Canada Dial-in Number: 888-596-4144 Replay Dial-in Number: 800-770-2030 International Dial-in Number: 646-968-2525 Replay International Dial-in Number: 609-800-9909 Conference ID: 4980126 Conference ID: 4980126 About BioMarin BioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The San Rafael, California-based company, founded in 1997, has a proven track record of innovation with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin pursues treatments that offer new possibilities for patients and families around the world navigating rare or difficult to treat genetic conditions. To learn more, please visit www.biomarin.com . 5 Forward-Looking Statements This pr
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.